All News

The questions that Dr. Amanda Ombrello (@NIH) asks when evaluating patients with recurrent fevers: -Age of onset -Frequency -Duration -Regularity -Height of fever -Prodromal symptoms #ACR19 @rheumnow

Jonathan Hausmann MD hausmannMD ( View Tweet)

Can lowering #uricacid improve hepatic fibrosis? Dr Naomi Schlesinger presented data from pegloticase #gout studies showing improvement/prevention of worsening vs pbo via the Fib-4 score Changes esp marked in pts with clinically important baseline Fib-4 score @RheumNow #ACR2019 https://t.co/8QUZvlcf57
Gout Study Group GoutGroup ( View Tweet)
PATCH: HCQ reduces congenital heart block (CHB) recurrence in babies born to Ro+ mothers w/ sibilings w/ CHB. This is encouraging data that further supports treatment induction in Ro+ pregnant pts to decrease fetal risk. https://t.co/0uU1zZP80l Plenary abs#1761 #ACR19 @RheumNow

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

“It’s so rare that a lupus clinical trial makes it to a plenary session...so cherish the moment!” -Dr Richard Furie on anifrolumab in SLE 🤣 #ACR19 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

TULIP1 Anifrolumab RCT in SLE Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS) Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6) Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed. #ACR19 Abst#1763 #ACRBest @RheumNow https://t.co/R4ily1Ubrz
Mike Putman EBRheum ( View Tweet)
Neonatal complete heart block is one to avoid. In Ro-pos mothers with a prev child with CHB, HCQ reduces rates from a historic 20% to 7.4% in the PATCH study. It seems we’re yet to fully realize the power of HCQ in conditions like these! @nyuschoolofmed #ACR19 ABST1761 @RheumNow https://t.co/TMzmq6TjJx
David Liew drdavidliew ( View Tweet)
#ACR19 @Rheumnow ABS1217 pegadricase (0.2 mg/kg) +ImmTOR (0.15 mg/kg) selected for HtoH study of SEL-212 vs pegloticase based on Ph2T result showing addition of ImmTOR at ≥0.1 mg/kg ⬇️ ADA formation & 66% of pts maintained sUA levels < 6 mg/dL at Wk20.

Olga Petryna DrPetryna ( View Tweet)

Loving the aesthetics of the #ACR19 conference center this year. @RheumNow https://t.co/MOZgNDlfzw
Dr. Paul Sufka psufka ( View Tweet)
HOPE results: 6 week tapering treatment with po prednisolone in HOA pts improved VAS scores and US synovitis. Will this change the way you approach HOA? https://t.co/0MtW7esExU Plenary abs#1760 #ACR19 @RheumNow https://t.co/U5SStHuJoh

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Over the last 10 years racial and ethnic minorities are significantly underrepresented in rheumatoid arthritis clinical trials with no hope for improvement in the future. How applicable are these results when they do not reflect the population? #ACR19 abstract# 1160 https://t.co/WNSGfyCSKu
Dr. John Cush RheumNow ( View Tweet)
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

#acr19 @rheumnow FDA notes w/Rheum Meds: 1. ⬇️apremilast dose in Apremilast to 30 mg/d for pt with severe CKD 2. Ok to use RTX in kids 2+ years old 3. Maintenance RTX 500 mg x2 the 500 mg q6mo x18 mo after induction Rx for GPA/MPA (kids use 250 mg/m2 dose then 250 mg/m2 q6 mo

k dao KDAO2011 ( View Tweet)

Abstr#1758: In pts with MSK symptoms and +antiCCP, those at high risk of developing RA had tenosynovitis, higher levels of IL-6 and ACPAs. #ACR2019 @RheumNow #RA #rheumatoidarthritis

Maeve Gamble MaeveGamble ( View Tweet)

Some hand OA patients with an inflammatory phenotype have structural benefit from lower dose MTX (but no difference with pain or function, but no difference with adverse events). Why the disconnect? And what’s a rheumatologist to do? Nice, France #ACR19 ABST1759 @RheumNow https://t.co/4SvWzps9DU
David Liew drdavidliew ( View Tweet)
The neutrophil nets take the win with nemaline rod myopathy which an be associated with congenital abnormality or HIV. Knowledge Bowl #ACRbest #ACR19 @RheumNow https://t.co/oIhWrcDUP5
Dr. Rachel Tate uptoTate ( View Tweet)
Great discussion on OA today at the Plenary session. #ACR19 @RheumNow What would you try in your erosive OA patients who have failed conservative therapy (hand therapy, analgesics and NSAIDs)?

Maeve Gamble MaeveGamble ( View Tweet)

@RheumNow What about pred for hand OA? Well PNL 10 has an effect while you're taking it, with reduction of synovial thickening, and in this study was well tolerated. Stop taking it, and you're back to baseline. Leiden #ACR19 ABST 1760 @RheumNow https://t.co/aw4UNHol7J
David Liew drdavidliew ( View Tweet)
Nice data in r-axSpA treated with ixekizumab showing improvements in fatigue, pain and sleep #ACR19 @RheumNow Abs 1510 https://t.co/raBP0Sv5bs
Philip Robinson philipcrobinson ( View Tweet)
Nice data from @Drbeckyg on patient self joint counts in #rheumatoid. This data supports patients ‘doing it for themselves’ to channel some Eurythmics. #ACR19 @RheumNow Abs 1366 https://t.co/MgFpiDKO7W
Philip Robinson philipcrobinson ( View Tweet)
So proud of our Chan Mi Lee abstr#1717 comparing brain histopath in PACNS vs other causes of CNS vasculitis. Intramural inflammatory infiltrate more specific than perivascular @RulaHajjAliMD @LCalabreseDO @RheumNow #ACR19 @CleClinicMD #cleclinicrheum https://t.co/CpQH4Ezxzd
Cassandra Calabrese CCalabreseDO ( View Tweet)
×